Blood test could help kids avoid harmful steroid side effects after transplant
NCT ID NCT05090384
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a blood test (GVHD biomarkers) can help doctors safely reduce steroid doses in children with graft-versus-host disease (GVHD) after a bone marrow transplant. Fifty children with newly diagnosed GVHD received prednisone, and those with low biomarker levels and good clinical response had their steroids tapered quickly. The goal was to see if this approach could maintain treatment success while reducing short- and long-term steroid side effects like infections, bone damage, and growth problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prednisone
What this could lead to
If successful, this approach could reduce steroid side effects in children with GVHD while maintaining treatment effectiveness.
What could go wrong
This is a small Phase 2 trial with only 50 participants, so results may not apply to all children. The biomarker test may not accurately predict who can safely taper steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE EFFECTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Medical College of Wisconsin / Children's Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Texas Children's Hospital, Baylor College of Medicine
Houston, Texas, 77030, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5S, Canada
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37235, United States